Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Molecular Variants of Sars-Cov-2: Antigenic Properties and Current Vaccine Efficacy Publisher Pubmed



Rayati Damavandi A1 ; Dowran R1, 2 ; Al Sharif S3 ; Kashanchi F3 ; Jafari R4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Students’ Scientific Research Center, Exceptional Talents Development Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Laboratory of Molecular Virology, School of Systems Biology, George Mason University, Manassas, VA, United States
  4. 4. Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran
  5. 5. Hematology, Immune Cell Therapy, and Stem Cell Transplantation Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran

Source: Medical Microbiology and Immunology Published:2022


Abstract

An ongoing pandemic of newly emerged SARS-CoV-2 has puzzled many scientists and health care policymakers around the globe. The appearance of the virus was accompanied by several distinct antigenic changes, specifically spike protein which is a key element for host cell entry of virus and major target of currently developing vaccines. Some of these mutations enable the virus to attach to receptors more firmly and easily. Moreover, a growing number of trials are demonstrating higher transmissibility and, in some of them, potentially more serious forms of illness related to novel variants. Some of these lineages, especially the Beta variant of concern, were reported to diminish the neutralizing activity of monoclonal and polyclonal antibodies present in both convalescent and vaccine sera. This could imply that these independently emerged variants could make antiviral strategies prone to serious threats. The rapid changes in the mutational profile of new clades, especially escape mutations, suggest the convergent evolution of the virus due to immune pressure. Nevertheless, great international efforts have been dedicated to producing efficacious vaccines with cutting-edge technologies. Despite the partial decrease in vaccines efficacy against worrisome clades, most current vaccines are still effective at preventing mild to severe forms of disease and hospital admission or death due to coronavirus disease 2019 (COVID-19). Here, we summarize existing evidence about newly emerged variants of SARS-CoV-2 and, notably, how well vaccines work against targeting new variants and modifications of highly flexible mRNA vaccines that might be required in the future. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Other Related Docs
11. Structural Evolution of Delta Lineage of Sars-Cov-2, International Journal of Biological Macromolecules (2023)
37. Implications Derived From S-Protein Variants of Sars-Cov-2 From Six Continents, International Journal of Biological Macromolecules (2021)
41. Green Chemistry and Coronavirus, Sustainable Chemistry and Pharmacy (2021)
42. The Spike Protein Mutations and Its Effect on Sars-Cov-2 Pathogenesis, Journal of Cellular and Molecular Anesthesia (2021)
49. Immune Profiling of Sars-Cov-2; What We Know and What We Don’T Know, Iranian Journal of Allergy# Asthma and Immunology (2023)